Atty's Docket:101195-54
DORKEN et al.,

AMENDMENTS TO THE CLAIMS

1. (Currently amended) Gene transfer vector, comprising

[-] (a) the YB-1 promoter, its mutants or deletion variants,

[-] (b) a transgene or the cDNA of a transgene

[-] (c) two multi-cloning sites (MCS) between which is ~~suited to cutting out the transgene for restriction enzymes surrounding~~ the transgene.

2. Gene transfer vector according to Claim 1, wherein the transgene is a therapeutic gene.

3. Gene transfer vector according to Claim 1, wherein the transgene is a reporter gene.

4. (Withdrawn)

5. (Withdrawn)

6. (Previously amended) Gene transfer vector according to Claim 1, wherein a regulating element is additionally inserted into the vector.

7. (Previously amended) Gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) contain at least 3 enzyme restriction sites interfaces for restriction enzymes.

8. (Currently amended) Gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) each comprise between 5-10 ~~contain enzyme~~ restriction enzyme sites ~~for restriction enzymes 5-10~~.

9. (Previously amended) Gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) for restriction enzymes contain no enzyme restriction sites occurring within the sequences of the YB-1 promoter.

10. (Previously amended) Gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) contain sticky enzyme restriction sites and blunt enzyme restriction sites for restriction enzymes.

11. (New) The vector of claim 1, wherein it is in a form suitable for *in vivo* transgene expression.

12. (New) A method of elevating the serum level of trangene product comprising the steps of

(a) preparing the vector of claim 11,

(b) administering said vector to a mammal, and

(c) measuring the serum level of the mammal at various times after administering the vector.